Get insights on the upcoming HOPE 3 phase 3 trial, key endpoints, and investment risks for CAPR. Learn what to watch in ...

Capricor Therapeutics is advancing deramiocel (CAP-1002) for DMD cardiomyopathy. Click here to find out why CAPR stock is a ...

Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its ...

Capricor Therapeutics (CAPR) announced a regulatory update for its Biologics License Application for Deramiocel, the Company’s investigational ...

Capricor (CAPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Capricor Therapeutics (NASDAQ:CAPR) added ~5% in the premarket on Thursday after the cell therapy developer said that during ...

SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today ...

Two months after its treatment for Duchenne-related cardiomyopathy was rejected, the company aligned with the agency on a ...

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced a regulatory update for its Biologics ...

LOS ANGELES, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) investors of a class action representing investors ...

NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.

NEW YORK - September 15, 2025 ( NEWMEDIAWIRE) - Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of a class action securities lawsuit.